Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/69418
Title: Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
Authors: Luz Couce, Maria
Sanchez-Pintos, Paula
Aldamiz-Echevarria, Luis
Vitoria, Isidro
Navas, Victor
Martin-Hernandez, Elena
Garcia-Volpe, Camila
Pintos, Guillem
Peña Quintana, Luis 
Hernandez, Tomas
Gil, David
Sanchez-Valverde, Felix
Bueno, Maria
Roca, Iria
Lopez-Ruzafa, Encarna
Diaz-Fernandez, Carmen
UNESCO Clasification: 32 Ciencias médicas
Keywords: Nephrocalcinosis
Phenotype
Severe liver dysfunction
Tubulopathy
Tyrosine
Issue Date: 2019
Journal: Medicine 
Abstract: Treatment with nitisinone (NTBC) has brought about a drastic improvement in the treatment and prognosis of hereditary tyrosinemia type I (HT1). We conducted a retrospective observational multicentric study in Spanish HT1 patients treated with NTBC to assess clinical and biochemical long-term evolution.We evaluated 52 patients, 7 adults and 45 children, treated with NTBC considering: age at diagnosis, diagnosis by clinical symptoms, or by newborn screening (NBS); phenotype (acute/subacute/chronic), mutational analysis; symptoms at diagnosis and clinical course; biochemical markers; doses of NTBC; treatment adherence; anthropometric evolution; and neurocognitive outcome.The average follow-up period was 6.1 ± 4.9 and 10.6 ± 5.4 years in patients with early and late diagnosis respectively. All patients received NTBC from diagnosis with an average dose of 0.82 mg/kg/d. All NBS-patients (n = 8) were asymptomatic at diagnosis except 1 case with acute liver failure, and all remain free of liver and renal disease in follow-up. Liver and renal affectation was markedly more frequent at diagnosis in patients with late diagnosis (P < .001 and .03, respectively), with ulterior positive hepatic and renal course in 86.4% and 93.2% of no-NBS patients, although 1 patient with good metabolic control developed hepatocarcinoma.Despite a satisfactory global nutritional evolution, 46.1% of patients showed overweight/obesity. Interestingly lower body mass index was observed in patients with good dietary adherence (20.40 ± 4.43 vs 24.30 ± 6.10; P = .08) and those with good pharmacological adherence (21.19 ± 4.68 vs 28.58 ± 213.79).intellectual quotient was ≥85 in all NBS- and 68.75% of late diagnosis cases evaluated, 15% of which need pedagogical support, and 6.8% (3/44) showed school failure.Among the 12 variants identified in fumarylacetoacetate hydrolase gene, 1 of them novel (H63D), the most prevalent in Spanish population is c.554-1 G>T.After NTBC treatment a reduction in tyrosine and alpha-fetoprotein levels was observed in all the study groups, significant for alpha-fetoprotein in no NBS-group (P = .03), especially in subacute/chronic forms (P = .018).This series confirms that NTBC treatment had clearly improved the prognosis and quality of life of HT1 patients, but it also shows frequent cognitive dysfunctions and learning difficulties in medium-term follow-up, and, in a novel way, a high percentage of overweight/obesity.
URI: http://hdl.handle.net/10553/69418
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000017303
Source: Medicine [ISSN 0025-7974], v. 98 (39), e17303
Appears in Collections:Artículos
Thumbnail
Adobe PDF (397,27 kB)
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.